netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Results

Looking for Infliximab found 34 matches

Formulary items 5 matches
   
Open monograph to display formulary status BNF Category
  Infliximab Gastro-intestinal system - Tumor necrosis factor alpha (TNF-a) inhibitors - 01.05.03
  Infliximab Gastro-intestinal system - Tumor necrosis factor alpha (TNF-a) inhibitors - 01.05.03
  Infliximab Malignant disease and immunosuppression - Drugs for cytotoxic-induced side-effects - 08.01
  Infliximab Musculoskeletal and joint diseases - Cytokine modulators - 10.01.03
  Infliximab Skin - Drugs affecting the immune response - 13.05.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section NICE TA134: Infliximab for the treatment of adults with psoriasis (13.05.03)
link in drug section NICE TA163: Infliximab for acute exacerbations of ulcerative colitis (01.05.03)
link in drug section NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease (01.05.03)
link in drug section NICE TA195: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA195:Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (10.01.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (13.05.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis (10.01.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (01.05.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)
link in drug section NICE TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed (10.01.03)




Document Library Items Found

 
netFormulary